These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23613764)

  • 1. Combined approaches for drug design points the way to novel proline racemase inhibitor candidates to fight Chagas' disease.
    Berneman A; Montout L; Goyard S; Chamond N; Cosson A; d'Archivio S; Gouault N; Uriac P; Blondel A; Minoprio P
    PLoS One; 2013; 8(4):e60955. PubMed ID: 23613764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designed mono- and di-covalent inhibitors trap modeled functional motions for Trypanosoma cruzi proline racemase in crystallography.
    Amaral PA; Autheman D; de Melo GD; Gouault N; Cupif JF; Goyard S; Dutra P; Coatnoan N; Cosson A; Monet D; Saul F; Haouz A; Uriac P; Blondel A; Minoprio P
    PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006853. PubMed ID: 30372428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prodrugs as new therapies against Chagas disease: in vivo synergy between Trypanosoma cruzi proline racemase inhibitors and benznidazole.
    de Melo GD; Coatnoan N; Gouault N; Cupif JF; Renault J; Cosson A; Uriac P; Blondel A; Minoprio P
    J Glob Antimicrob Resist; 2022 Mar; 28():84-89. PubMed ID: 34929377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irreversible inhibitors of the proline racemase unveil innovative mechanism of action as antibacterial agents against Clostridioides difficile.
    Gateau C; Melo GD; Uriac P; Tasseau O; Renault J; Blondel A; Gouault N; Barbut F; Minoprio P
    Chem Biol Drug Des; 2022 Apr; 99(4):513-526. PubMed ID: 34918458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical characterization of proline racemases from the human protozoan parasite Trypanosoma cruzi and definition of putative protein signatures.
    Chamond N; Grégoire C; Coatnoan N; Rougeot C; Freitas-Junior LH; da Silveira JF; Degrave WM; Minoprio P
    J Biol Chem; 2003 May; 278(18):15484-94. PubMed ID: 12735293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi.
    Freymann DM; Wenck MA; Engel JC; Feng J; Focia PJ; Eakin AE; Craig SP
    Chem Biol; 2000 Dec; 7(12):957-68. PubMed ID: 11137818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Trypanosoma cruzi proline racemase affects host-parasite interactions and the outcome of in vitro infection.
    Coutinho L; Ferreira MA; Cosson A; Batista MM; Batista Dda G; Minoprio P; Degrave WM; Berneman A; Soeiro Mde N
    Mem Inst Oswaldo Cruz; 2009 Dec; 104(8):1055-62. PubMed ID: 20140365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
    Monteiro ME; Lechuga G; Lara LS; Souto BA; Viganó MG; Bourguignon SC; Calvet CM; Oliveira FOR; Alves CR; Souza-Silva F; Santos MS; Pereira MCS
    Eur J Med Chem; 2019 Nov; 182():111610. PubMed ID: 31434040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proline racemases are conserved mitogens: characterization of a Trypanosoma vivax proline racemase.
    Chamond N; Cosson A; Coatnoan N; Minoprio P
    Mol Biochem Parasitol; 2009 Jun; 165(2):170-9. PubMed ID: 19428664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of proline analogs as trypanocidal agents through the inhibition of a Trypanosoma cruzi proline transporter.
    Sayé M; Fargnoli L; Reigada C; Labadie GR; Pereira CA
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2913-2921. PubMed ID: 28844978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of substrate - analogue inhibitors of Trypanosoma cruzi ribose 5-phosphate isomerase type B.
    Gonzalez SN; Mills JJ; Maugeri D; Olaya C; Laguera BL; Enders JR; Sherman J; Rodriguez A; Pierce JG; Cazzulo JJ; D'Antonio EL
    Bioorg Med Chem Lett; 2021 Jan; 32():127723. PubMed ID: 33249135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic immunization converts the trypanosoma cruzi B-Cell mitogen proline racemase to an effective immunogen.
    Bryan MA; Norris KA
    Infect Immun; 2010 Feb; 78(2):810-22. PubMed ID: 19917711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trypanosoma cruzi proline racemases are involved in parasite differentiation and infectivity.
    Chamond N; Goytia M; Coatnoan N; Barale JC; Cosson A; Degrave WM; Minoprio P
    Mol Microbiol; 2005 Oct; 58(1):46-60. PubMed ID: 16164548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069.
    Sayé M; Gauna L; Valera-Vera E; Reigada C; Miranda MR; Pereira CA
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007481. PubMed ID: 31961864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel cruzain inhibitors for the treatment of Chagas' disease.
    Rogers KE; Keränen H; Durrant JD; Ratnam J; Doak A; Arkin MR; McCammon JA
    Chem Biol Drug Des; 2012 Sep; 80(3):398-405. PubMed ID: 22613098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.
    Schormann N; Velu SE; Murugesan S; Senkovich O; Walker K; Chenna BC; Shinkre B; Desai A; Chattopadhyay D
    Bioorg Med Chem; 2010 Jun; 18(11):4056-66. PubMed ID: 20452776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synthesis and kinetic evaluation of aryl α-aminophosphonates as novel inhibitors of T. cruzi trans-sialidase.
    Chen Z; Marcé P; Resende R; Alzari PM; Frasch AC; van den Elsen JMH; Crennell SJ; Watts AG
    Eur J Med Chem; 2018 Oct; 158():25-33. PubMed ID: 30199703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aryl ureas represent a new class of anti-trypanosomal agents.
    Du X; Hansell E; Engel JC; Caffrey CR; Cohen FE; McKerrow JH
    Chem Biol; 2000 Sep; 7(9):733-42. PubMed ID: 10980453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of new growth inhibitors of Trypanosoma cruzi (epimastigotes).
    Schvartzapel AJ; Zhong L; Docampo R; Rodriguez JB; Gros EG
    J Med Chem; 1997 Jul; 40(15):2314-22. PubMed ID: 9240347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Novel Functionalized Carbohydrazonamides Designed as Chagas Disease Drug Candidates.
    do Nascimento MSS; Câmara VRF; da Costa JS; Barbosa JMC; Lins ASM; Salomão K; de Castro SL; Carvalho SA; da Silva EF; Fraga CAM
    Med Chem; 2020; 16(6):774-783. PubMed ID: 31244442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.